Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Long-term, priority isotope access is intended to support Telix's early-stage alpha therapy pipeline and third-party development programs.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Telix Pharmaceuticals (TLX) and Ekalia announced a collaboration to develop U.S. production of astatine-211, an isotope being investigated for targeted cancer therapy. The framework provides for the first IBA alpha-beam cyclotron to be installed and operated at Telix's RLS Trevose site near Philadelphia.
The collaboration secures long-term, priority isotope access for Telix's alpha therapy pipeline. Telix expects it to support early-stage candidates including TLX102-Tx, being evaluated for glioblastoma and leptomeningeal disease. Production is also intended to support third-party academic and industry programs. The parties will evaluate additional RLS installations as demand develops; the initial site is intended to establish a repeatable production model.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointIsotope access secured on a long-term, priority basis for Telix's alpha therapy pipeline.
- Minor point. Forward-looking: it has not happened yet and may not happen.First IBA alpha-beam cyclotron planned for installation and operation at Telix's RLS Trevose site.
- Minor point. Forward-looking: it has not happened yet and may not happen.Pipeline support is expected for early-stage candidates including TLX102-Tx, evaluated for glioblastoma and leptomeningeal disease.
- Minor point. Forward-looking: it has not happened yet and may not happen.Production capacity is intended to support third-party academic and industry programs.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional RLS installations will be evaluated as demand develops.
Negative
- Minor pointProduction collaboration remains a framework, with the first U.S. installation still planned rather than operational.
Key Terms
astatine-211 medical
targeted alpha therapy medical
alpha-beam cyclotron technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT).
- Secures long-term, priority isotope access for Telix's alpha therapy pipeline, including its TLX102-Tx candidate for glioblastoma and leptomeningeal disease, while also supporting third-party academic and industry programs.
- First IBA alpha-beam cyclotron to be installed and operated at Telix's RLS Radiopharmacies site near Philadelphia, PA.
- Leverages Telix's vertically integrated U.S. manufacturing and distribution platform, with a framework providing for the parties to evaluate additional installations at RLS sites as demand for 211At develops.
MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, today announced a collaboration to advance scalable United States (U.S.) production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy.
The collaboration brings together IBA's specialized alpha-beam cyclotron technology, Framatome's nuclear and isotope production expertise, and Telix's U.S. radiopharmacy and “last-mile” infrastructure, clinical portfolio and radiopharmaceutical development capabilities. The alliance expands into the U.S. the strategic partnership formed by IBA and Framatome in Europe to advance industrial-scale ²¹¹At production. The first installation at RLS Trevose is intended to establish a reproducible production model, with the potential for further rollout across the RLS network as demand develops.
Astatine-211 is recognized as a promising alpha-emitting radioisotope for the development of innovative cancer treatments1. However, its broader adoption remains constrained by the availability of sufficient production capacity2. The collaboration is intended to improve robust, reliable, and timely access to 211At for research and clinical development through a network of production sites in close proximity to clinical centers, helping to further establish theranostics as a cornerstone of precision oncology.
For Telix, the collaboration is expected to support the development of several early-stage therapeutic candidates, including TLX102-Tx (211At astato-L-phenylalanine), a TAT being evaluated for glioblastoma and leptomeningeal disease, as well as future 211At programs. The collaboration is also intended to provide production capacity for third-party academic and industry programs, helping to expand the U.S. 211At development ecosystem.
Bruno Scutnaire, CEO of Ekalia (company in formation) said: “IBA’s specialized alpha-beam cyclotron technology is designed to enable reliable astatine-211 production at the point of need. Building on our work with Framatome in Europe, Telix’s U.S. infrastructure enables us to move faster towards establishing our first U.S. production unit, while laying the foundations for Ekalia’s broader development in the country.”
Chad Watkins, General Manager, Isotope Strategy at Telix, continued: "Owning the path from isotope to patient is central to our development and commercialization strategy. This collaboration gives Telix a dedicated, long-term source of astatine-211 to advance our alpha therapy pipeline, and demonstrates the strategic value of the RLS platform as a host for next-generation isotope production in the U.S. We are delighted to partner with IBA and Framatome, two global leaders in this field, to help advance reliable, scalable astatine-211 production."
About EKALIA
Ekalia (company in formation) is the joint venture between IBA (Ion Beam Applications, EURONEXT) and Framatome, dedicated to deploying an international network of industrial-scale Astatine-211 production sites close to customers, making this promising radioisotope available for future targeted cancer therapies. Jointly owned by the two partners, the new company combines IBA's cutting edge cyclotron and isotope production technologies with Framatome's nuclear industrial expertise. Together, the two companies intend to establish a network of production sites across Europe and North America.
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.
Telix's commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries, including the U.S.; Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging; and Pixclara® (floretyrosine F 18), approved by the FDA for glioma imaging. The Company's late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan 131I) in recurrent glioblastoma, and TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan) in kidney cancer. These are complemented by a deep pipeline of next-generation candidates including TLX102-Tx (211At astato-L-phenylalanine), a 211At labelled TAT candidate being evaluated for glioblastoma and leptomeningeal disease.
Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X, and Facebook.
| Investor Relations Annie Kasparian annie.kasparian@telixpharma.com Charlene Jaw charlene.jaw@telixpharma.com | Media Eliza Schleifstein 917.763.8106 (Mobile) Eliza@schleifsteinpr.com |
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s ability to operationalize and derive value from collaborations, partnerships and similar arrangements; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
________________________
1 Lindegren et al. EJNMMI Radioph. and Chem. (2026) 11, 15 doi:10.1186/s41181-026-00428-0
2 Albertsson P et al; Frontiers in Med (2023),9, 1076210: doi:10.3389/fmed.2022.1076210.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Telix and Ekalia astatine-211 collaboration provide for?
The collaboration provides for U.S. astatine-211 production and long-term, priority isotope access for Telix's alpha therapy pipeline. The first IBA alpha-beam cyclotron is planned for Telix's RLS Trevose site near Philadelphia, with production also intended to support third-party academic and industry programs.
Which Telix drug candidate is expected to benefit from the Ekalia collaboration?
Telix expects the collaboration to support TLX102-Tx, an early-stage targeted alpha therapy candidate being evaluated for glioblastoma and leptomeningeal disease. It is also expected to support other early-stage therapeutic candidates and future astatine-211 programs.